Biote (BTMD) Current Deferred Revenue (2021 - 2026)

Biote's Current Deferred Revenue history runs 6 years deep, the most recent figure standing at $2.8 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue fell 6.19% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $2.8 million (down 6.19% YoY), while the FY2025 annual figure was $3.0 million, up 1.89% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $2.8 million, down from $3.0 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $3.2 million in Q3 2025, with the low at $1.9 million in Q2 2022.
• The 5-year median for Current Deferred Revenue is $2.9 million (2024), against an average of $2.7 million.
• The sharpest annual moves came in 2023 and 2026: Current Deferred Revenue soared 52.77% in 2023, then retreated 6.19% in 2026.
• Biote's Current Deferred Revenue stood at $2.0 million in 2022, then jumped by 52.77% to $3.0 million in 2023, then dropped by 1.37% to $3.0 million in 2024, then climbed by 1.89% to $3.0 million in 2025, then dropped by 5.6% to $2.8 million in 2026.
• Business Quant data shows BTMD's Current Deferred Revenue at $2.8 million in Q1 2026, $3.0 million in Q4 2025, and $3.2 million in Q3 2025.